Solid Tumor Testing Market Synopsis

Solid Tumor Testing Market Size Was Valued at USD 27.3 Billion in 2023, and is Projected to Reach USD 51.4 Billion by 2032, Growing at a CAGR of 7.3% From 2024-2032.

The Solid Tumor Testing Market encompasses all the diagnostic products and technologies that are used for identifying, staging, and managing solid tumours in different organs such as the breast, lung, prostate, colon and more. Malignant neoplasms are also called solid tumors, which are unusual growths of tissues as unlike benign tumors they tend not to harbor cysts or liquid components. It can be either cystic (non malignant) or sclicular (malignant) and early diagnosis of the tumor is highly recommending for successful prognosis. The market includes diagnostic such facilities as NGS, IHC, PCR, and other molecular profiling that allows identifying specific features of tumoral tissues and contributing to creation of individual therapy regimens that improve patients’ quality of life.

• Solid Tumor Testing Market has experienced a steady growth over the recent past as a result of innovation in precision medicine and high incident rate of cancer across the world. Abundant demands for early detection and defining the genetic markers associated with particular types of cancer has led to establishment of new testing technologies. It is growing because healthcare providers and oncologists are in search of better diagnostic and prognostic tools and treatment paired tumor markers to solid tumor. The next generation sequencing (NGS) has become the other driver enabling identification of multiple genetic mutations at once as well as the additional understanding of the tumor biology. In addition, liquid biopsy, which is currently receiving a lot of attention for early cancer detection and monitoring through blood samples is changing the testing paradigm.
• Also driving this market are technology developments and regulatory clearances and collaborations between diagnostic companies and the pharma industries. Combined solutions for determining tumor characteristics compatible with particular treatments are enhancing the accuracy of cancer treatment. The global cancer incidence rate is on the rise, particularly in the geriatric population due to increased awareness regarding diagnosis and individualized treatments driving the market. Governments and healthcare organizations are also spending on research and diagnostics especially within the developing world where take on cancer has taken root. But, high costs linked with higher end diagnostic tools and issues related to reimbursement may act as a restraint for the market, primarily in the less developed world.

Solid Tumor Testing Market Trend Analysis

Growing Adoption of NGS and Liquid Biopsies

• A primary driver influencing the growth in the Solid Tumor Testing Market is the rising use of NGS and liquid biopsies. Whole-genome sequencing by NGS also provides an opportunity for sequencing only interesting regions or the entire genome at the same time with the identification of many mutations at once. This is especially so in detecting alterations that are not very frequent but can nonetheless advance the cancer or make it resistant to treatment. While blood-based diagnostics allows for identifying and tracking of tumor, liquid biopsies also acts as less invasive methods for biopsying ctDNA. It is becoming more popular as an additional approach to tissue biopsy where patients undergo tests frequently without the need for invasive procedures. Similarly there is increased use, research and clinical trials supporting these technologies and hence more prominence in the early diagnosis and specific treatment of solid tumours is expected for both NGS and liquid biopsies.

Expanding Role of Precision Medicine

• The opportunities in the Solid Tumor Testing Market are analyzed with the focus on the emerging concept of precision medicine. PM is a concept of providing a therapy uniquely designed for a patient, with regard to his or her genetic profile as well as the biomolecular details of the tumour. As new tests on comprehensive genomic profiling and molecular diagnostics become more widely available, oncologists are in a position to identify biomarkers and genetic changes that fuel tumor development and offer better treatment regimens. This approach minimizes the adverse side effects that mostly accompany the treatments while at the same time enhancing the …success rate of the treatments.
• In addition, the increased number of combined therapy and Injection solutions introduced by the pharmaceutical industry to people will create the conditions for the introduction of neo-target therapy and immunotherapy for cancer, and the companion diagnostics that will help detect these diseases will also increase. As well, efforts underway to advance these more sophisticated diagnostics and make them more readily available and less costly, especially within developing nations, will open up new sources of opportunity for market participants.

Solid Tumor Testing Market Segment Analysis:

Solid Tumor Testing Market Segmented on the basis of type, application and end user.

By Type, Genetic Testing segment is expected to dominate the market during the forecast period

• The Genetic Testing segment is expected to remain the largest segment of the Solid Tumor Testing Market throughout the forecast period due to the rising topicality of precision medicine and the continuous demand for individualised cancer treatments.. The molecular profiling of solid tumors is essential for determining a unique set of gene mutations and molecular changes that underlie tumor growth and for guiding treatment strategies based on the results. It also improves the quality of therapy and the risk of side effects.
• Availability and accuracy of molecular diagnostics especially NGS has played a major role in increased use of genetic testing. In addition, the rising patient and healthcare professional consciousness on the early detection of cancer and an increased possibility of judging the propensity towards cancer based on DNA make this segment popular. Due to constant improvements in the tests and genetic testing products, and increased use in continued cancer treatment, the segment is anticipated to maintain its leadership in the given forecast period.

By Application, Prostate segment expected to held the largest share

• The Prostate is recognized to be the largest segment within the Solid Tumor Testing Market owing to the frequent occurrence of prostate cancer together with an increased clientele’s consciousness about early detection and treatment.. This is particularly true for prostate cancer, which is one of the most prevalent forms of cancer in men and the frequency of which grows with the aging population, thus making the diagnostic tools needed for the disease even more relevant. PSA examination is a part of radical diagnostics and treatment of this disease, as well as using modern genetic and molecular testing methods.
• In addition, developments in screening tools like liquid biopsies and NGs have improved the techniques used for diagnosing the disease at an early stage, make it easier to intervene and develop individual patient treatment plans. The focus on precision medicine which relies on molecular features of tumors to define the treatment, also increases the number of related testing for prostate. Therefore, it is predictable that in the context of the share of the entire market within the forecast period, the Prostate segment has a higher research emphasis on enhancing the quality of life of patients with prostate cancer.

Solid Tumor Testing Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• In 2023, North America remains the market leader of the global Solid Tumor Testing Market, mainly due to the United States. The dominance of the region can be explained by factors such as a developed health care system, high rates of cancer incidence, investment in innovations and R & D special for early diagnostics of oncological diseases. North America had a market share of about 40% in 2023 because of the rising government funding for the cancer related research, high usage of advanced diagnostic methods and prominence of excellent biotech and pharma companies. This has witnessed strong growth in demand for a more personalized approach of healthcare and we have also seen introduction of new diagnostic tests getting approval to further drive the market growth in this region.

Active Key Players in the Solid Tumor Testing Market

• Abbott Laboratories (United States)
• Agilent Technologies (United States)
• Biocept, Inc. (United States)
• Bio-Rad Laboratories (United States)
• Danaher Corporation (United States)
• Foundation Medicine (United States)
• Guardant Health (United States)
• Illumina, Inc. (United States)
• Invitae Corporation (United States)
• Myriad Genetics (United States)
• NeoGenomics Laboratories (United States)
• Qiagen N.V. (Netherlands)
• Roche Diagnostics (Switzerland)
• Siemens Healthineers (Germany)
• Thermo Fisher Scientific (United States)
• Other key Players

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Solid Tumor Testing Market by Type
 4.1 Solid Tumor Testing Market Snapshot and Growth Engine
 4.2 Solid Tumor Testing Market Overview
 4.3 Genetic Testing
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Genetic Testing: Geographic Segmentation Analysis
 4.4 Conventional Testing
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Conventional Testing: Geographic Segmentation Analysis

Chapter 5: Solid Tumor Testing Market by Application
 5.1 Solid Tumor Testing Market Snapshot and Growth Engine
 5.2 Solid Tumor Testing Market Overview
 5.3 Prostate
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Prostate: Geographic Segmentation Analysis
 5.4 Breast
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Breast: Geographic Segmentation Analysis
 5.5 Colorectal
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Colorectal: Geographic Segmentation Analysis
 5.6 Endometrial
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Endometrial: Geographic Segmentation Analysis
 5.7 Lung
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 Lung: Geographic Segmentation Analysis
 5.8 Melanoma
  5.8.1 Introduction and Market Overview
  5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.8.3 Key Market Trends, Growth Factors and Opportunities
  5.8.4 Melanoma: Geographic Segmentation Analysis
 5.9 Brain
  5.9.1 Introduction and Market Overview
  5.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.9.3 Key Market Trends, Growth Factors and Opportunities
  5.9.4 Brain: Geographic Segmentation Analysis
 5.10 Thyroid
  5.10.1 Introduction and Market Overview
  5.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.10.3 Key Market Trends, Growth Factors and Opportunities
  5.10.4 Thyroid: Geographic Segmentation Analysis
 5.11 Liver
  5.11.1 Introduction and Market Overview
  5.11.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.11.3 Key Market Trends, Growth Factors and Opportunities
  5.11.4 Liver: Geographic Segmentation Analysis
 5.12 Ovarian
  5.12.1 Introduction and Market Overview
  5.12.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.12.3 Key Market Trends, Growth Factors and Opportunities
  5.12.4 Ovarian: Geographic Segmentation Analysis

Chapter 6: Solid Tumor Testing Market by End User
 6.1 Solid Tumor Testing Market Snapshot and Growth Engine
 6.2 Solid Tumor Testing Market Overview
 6.3 Hospitals
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Hospitals: Geographic Segmentation Analysis
 6.4 Pharmaceutical and biotechnology companies
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Pharmaceutical and biotechnology companies: Geographic Segmentation Analysis
 6.5 Contract research organizations
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Contract research organizations: Geographic Segmentation Analysis
 6.6 Academic research institutions
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Academic research institutions: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Solid Tumor Testing Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions
  
 7.2 ABBOTT LABORATORIES (UNITED STATES)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 AGILENT TECHNOLOGIES (UNITED STATES)
 7.4 BIOCEPT
 7.5 INC (UNITED STATES)
 7.6 BIO-RAD LABORATORIES (UNITED STATES)
 7.7 DANAHER CORPORATION (UNITED STATES)
 7.8 FOUNDATION MEDICINE (UNITED STATES)
 7.9 GUARDANT HEALTH (UNITED STATES)
 7.10 ILLUMINA
 7.11 INC (UNITED STATES)
 7.12 INVITAE CORPORATION (UNITED STATES)
 7.13 MYRIAD GENETICS (UNITED STATES)
 7.14 NEOGENOMICS LABORATORIES (UNITED STATES)
 7.15 QIAGEN NV(NETHERLANDS)
 7.16 ROCHE DIAGNOSTICS (SWITZERLAND)
 7.17 SIEMENS HEALTHINEERS (GERMANY)
 7.18 THERMO FISHER SCIENTIFIC (UNITED STATES)
 7.19 OTHER ACTIVE PLAYERS

Chapter 8: Global Solid Tumor Testing Market By Region
 8.1 Overview
 8.2. North America Solid Tumor Testing Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Type
  8.2.4.1 Genetic Testing
  8.2.4.2 Conventional Testing
  8.2.5 Historic and Forecasted Market Size By Application
  8.2.5.1 Prostate
  8.2.5.2 Breast
  8.2.5.3 Colorectal
  8.2.5.4 Endometrial
  8.2.5.5 Lung
  8.2.5.6 Melanoma
  8.2.5.7 Brain
  8.2.5.8 Thyroid
  8.2.5.9 Liver
  8.2.5.10 Ovarian
  8.2.6 Historic and Forecasted Market Size By End User
  8.2.6.1 Hospitals
  8.2.6.2 Pharmaceutical and biotechnology companies
  8.2.6.3 Contract research organizations
  8.2.6.4 Academic research institutions
  8.2.7 Historic and Forecast Market Size by Country
  8.2.7.1 US
  8.2.7.2 Canada
  8.2.7.3 Mexico
 8.3. Eastern Europe Solid Tumor Testing Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Type
  8.3.4.1 Genetic Testing
  8.3.4.2 Conventional Testing
  8.3.5 Historic and Forecasted Market Size By Application
  8.3.5.1 Prostate
  8.3.5.2 Breast
  8.3.5.3 Colorectal
  8.3.5.4 Endometrial
  8.3.5.5 Lung
  8.3.5.6 Melanoma
  8.3.5.7 Brain
  8.3.5.8 Thyroid
  8.3.5.9 Liver
  8.3.5.10 Ovarian
  8.3.6 Historic and Forecasted Market Size By End User
  8.3.6.1 Hospitals
  8.3.6.2 Pharmaceutical and biotechnology companies
  8.3.6.3 Contract research organizations
  8.3.6.4 Academic research institutions
  8.3.7 Historic and Forecast Market Size by Country
  8.3.7.1 Bulgaria
  8.3.7.2 The Czech Republic
  8.3.7.3 Hungary
  8.3.7.4 Poland
  8.3.7.5 Romania
  8.3.7.6 Rest of Eastern Europe
 8.4. Western Europe Solid Tumor Testing Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Type
  8.4.4.1 Genetic Testing
  8.4.4.2 Conventional Testing
  8.4.5 Historic and Forecasted Market Size By Application
  8.4.5.1 Prostate
  8.4.5.2 Breast
  8.4.5.3 Colorectal
  8.4.5.4 Endometrial
  8.4.5.5 Lung
  8.4.5.6 Melanoma
  8.4.5.7 Brain
  8.4.5.8 Thyroid
  8.4.5.9 Liver
  8.4.5.10 Ovarian
  8.4.6 Historic and Forecasted Market Size By End User
  8.4.6.1 Hospitals
  8.4.6.2 Pharmaceutical and biotechnology companies
  8.4.6.3 Contract research organizations
  8.4.6.4 Academic research institutions
  8.4.7 Historic and Forecast Market Size by Country
  8.4.7.1 Germany
  8.4.7.2 UK
  8.4.7.3 France
  8.4.7.4 Netherlands
  8.4.7.5 Italy
  8.4.7.6 Russia
  8.4.7.7 Spain
  8.4.7.8 Rest of Western Europe
 8.5. Asia Pacific Solid Tumor Testing Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Type
  8.5.4.1 Genetic Testing
  8.5.4.2 Conventional Testing
  8.5.5 Historic and Forecasted Market Size By Application
  8.5.5.1 Prostate
  8.5.5.2 Breast
  8.5.5.3 Colorectal
  8.5.5.4 Endometrial
  8.5.5.5 Lung
  8.5.5.6 Melanoma
  8.5.5.7 Brain
  8.5.5.8 Thyroid
  8.5.5.9 Liver
  8.5.5.10 Ovarian
  8.5.6 Historic and Forecasted Market Size By End User
  8.5.6.1 Hospitals
  8.5.6.2 Pharmaceutical and biotechnology companies
  8.5.6.3 Contract research organizations
  8.5.6.4 Academic research institutions
  8.5.7 Historic and Forecast Market Size by Country
  8.5.7.1 China
  8.5.7.2 India
  8.5.7.3 Japan
  8.5.7.4 South Korea
  8.5.7.5 Malaysia
  8.5.7.6 Thailand
  8.5.7.7 Vietnam
  8.5.7.8 The Philippines
  8.5.7.9 Australia
  8.5.7.10 New Zealand
  8.5.7.11 Rest of APAC
 8.6. Middle East & Africa Solid Tumor Testing Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Type
  8.6.4.1 Genetic Testing
  8.6.4.2 Conventional Testing
  8.6.5 Historic and Forecasted Market Size By Application
  8.6.5.1 Prostate
  8.6.5.2 Breast
  8.6.5.3 Colorectal
  8.6.5.4 Endometrial
  8.6.5.5 Lung
  8.6.5.6 Melanoma
  8.6.5.7 Brain
  8.6.5.8 Thyroid
  8.6.5.9 Liver
  8.6.5.10 Ovarian
  8.6.6 Historic and Forecasted Market Size By End User
  8.6.6.1 Hospitals
  8.6.6.2 Pharmaceutical and biotechnology companies
  8.6.6.3 Contract research organizations
  8.6.6.4 Academic research institutions
  8.6.7 Historic and Forecast Market Size by Country
  8.6.7.1 Turkey
  8.6.7.2 Bahrain
  8.6.7.3 Kuwait
  8.6.7.4 Saudi Arabia
  8.6.7.5 Qatar
  8.6.7.6 UAE
  8.6.7.7 Israel
  8.6.7.8 South Africa
 8.7. South America Solid Tumor Testing Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Type
  8.7.4.1 Genetic Testing
  8.7.4.2 Conventional Testing
  8.7.5 Historic and Forecasted Market Size By Application
  8.7.5.1 Prostate
  8.7.5.2 Breast
  8.7.5.3 Colorectal
  8.7.5.4 Endometrial
  8.7.5.5 Lung
  8.7.5.6 Melanoma
  8.7.5.7 Brain
  8.7.5.8 Thyroid
  8.7.5.9 Liver
  8.7.5.10 Ovarian
  8.7.6 Historic and Forecasted Market Size By End User
  8.7.6.1 Hospitals
  8.7.6.2 Pharmaceutical and biotechnology companies
  8.7.6.3 Contract research organizations
  8.7.6.4 Academic research institutions
  8.7.7 Historic and Forecast Market Size by Country
  8.7.7.1 Brazil
  8.7.7.2 Argentina
  8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research